Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKP.L Regulatory News (SKP)

  • There is currently no data for SKP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Skyepharma PLC

29 Apr 2016 09:22

RNS Number : 8074W
SFM UK Management LLP
29 April 2016
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Identity of the person whose positions/dealings are being disclosed:

SFM UK Management LLP

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient

Quantum Partners LP

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Skyepharma PLC

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

N/A

(e) Date position held/dealing undertaken:

28th April 2016

(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?

NO

 

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ordinary GBp 100

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

1,363,992

1.28%

(2) Derivatives (other than options):

(3) Options and agreements to purchase/sell:

 

TOTAL:

1,363,992

1.28%

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ordinary GBp 100

Sale

 

5,626

GBP4.7846

Ordinary GBp 100

Sale

 

3,811

GBP4.7938

Ordinary GBp 100

Sale

 

137,571

GBP4.7857

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

29th April 2016

Contact name:

Jade Cornell

Telephone number:

020 7758 4800

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETVKLBLQZFFBBD
Date   Source Headline
9th Jun 20161:03 pmRNSForm 8.3 - Vectura Group Plc
9th Jun 201612:00 pmRNSForm 8.5 (EPT/RI) - Skyepharma Plc
9th Jun 201612:00 pmRNSForm 8.5 (EPT/RI) - Vectura Group PLC
9th Jun 201610:54 amRNSCourt sanction of Scheme of Arrangement
9th Jun 201610:51 amRNSForm 8.5 (EPT/RI) - Skyepharma PLC
9th Jun 20168:52 amRNSForm 8.5 (EPT/RI) - Skyepharma Plc
8th Jun 201612:25 pmRNSForm 8.5 (EPT/RI) - Skyepharma PLC Amendment
8th Jun 201612:00 pmRNSForm 8.5 (EPT/RI) - Vectura Group PLC
8th Jun 201612:00 pmRNSForm 8.5 (EPT/RI) - Skyepharma Plc
8th Jun 201610:24 amRNSForm 8.5 (EPT/RI) - Skyepharma PLC
8th Jun 20169:20 amRNSForm 8.5 (EPT/RI) - Skyepharma Plc
8th Jun 20168:32 amRNSHolding(s) in Company
7th Jun 20162:56 pmRNSTechnology License Agreement
7th Jun 20162:02 pmRNSForm 8.3 - Skyepharma Plc
7th Jun 20161:05 pmRNSForm 8.5 (EPT/RI) - Vectura Group PLC
7th Jun 201611:21 amRNSForm 8.5 (EPT/RI) - Skyepharma PLC
7th Jun 20169:06 amRNSForm 8.5 (EPT/RI) - Skyepharma Plc
6th Jun 20163:34 pmRNSForm 8.3 - Skyepharma Plc
6th Jun 20163:30 pmRNSForm 8.3 - [VEC/SKP]
6th Jun 20163:30 pmRNSForm 8.3 - [SKP/VEC]
6th Jun 20163:09 pmRNSForm 8.3 - [Skyepharma plc]
6th Jun 20162:51 pmRNSForm 8.3 - SKYEPHARMA PLC
6th Jun 20162:14 pmRNSForm 8.3 - Skyepharma Plc
6th Jun 20161:23 pmRNSForm 8.3 - Skyepharma Plc
6th Jun 201612:00 pmRNSForm 8.5 (EPT/RI) -Vectura Group PLC
6th Jun 201612:00 pmRNSForm 8.5 (EPT/RI) - Skyepharma Plc
6th Jun 201610:59 amRNSForm 8.5 (EPT/RI) - Skyepharma PLC
6th Jun 201610:03 amRNSForm 8.5 (EPT/RI) - Skyepharma Plc
6th Jun 20168:35 amRNSForm 8.3 - Vectura Group plc
3rd Jun 20163:30 pmRNSForm 8.3 - [VEC/SKP]
3rd Jun 20163:30 pmRNSForm 8.3 - [SKP/VEC]
3rd Jun 20163:20 pmRNSForm 8.3 - Skyepharma PLC
3rd Jun 20161:45 pmRNSForm 8.3 - Skyepharma Plc
3rd Jun 20161:23 pmRNSForm 8.3 - Skyepharma Plc
3rd Jun 201611:59 amRNSForm 8.5 (EPT/RI) - Vectura Group PLC
3rd Jun 201611:59 amRNSForm 8.5 (EPT/RI) - Skyepharma PLC
3rd Jun 201610:28 amRNSForm 8.5 (EPT/RI) - Skyepharma PLC
3rd Jun 20169:45 amRNSForm 8.3 - Skyepharma PLC
3rd Jun 20169:31 amRNSForm 8.5 (EPT/RI) - Skyepharma Plc
2nd Jun 20163:30 pmRNSForm 8.3 - [VEC/SKP]
2nd Jun 20163:30 pmRNSForm 8.3 - [SKP/VEC]
2nd Jun 20163:20 pmRNSForm 8.3 - Skyepharma PLC
2nd Jun 20161:33 pmRNSForm 8.3 - Skyepharma Plc
2nd Jun 201612:00 pmRNSForm 8.5 (EPT/RI) - Skyepharma Plc
2nd Jun 201612:00 pmRNSForm 8.5 (EPT/RI) - ve
2nd Jun 201610:32 amRNSForm 8.5 (EPT/RI) - Skyepharma PLC
2nd Jun 20169:54 amRNSForm 8.3 - Skyepharma PLC
2nd Jun 20169:10 amRNSForm 8.5 (EPT/RI) - Skyepharma Plc
1st Jun 20163:30 pmRNSForm 8.3 - [SKP/VEC]
1st Jun 20163:30 pmRNSForm 8.3 - [VEC/SKP]

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.